Rheumatoid Arthritis
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA). However, just a year after their introduction, evidence began to surface regarding the harmful side effects and withdrawal symptoms such as pain and fatigue that were independent of RA itself.
Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and
Sleep plays a critical role in regulating inflammation and overall health. In rheumatic diseases like lupus and rheumatoid arthritis (RA), disrupted sleep is common and can exacerbate symptoms and disease progression. Experts Dr. Al Kim, Patty Katz, and Dr. Yvonne Lee emphasized the importance of addressing sleep disturbances in these conditions.
Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk ACPA- patients.
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes. Advances in machine learning (ML) provide a promising avenue for predicting these flares, enabling proactive management and personalised interventions.
For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way for improved outcomes.

Dr. John Cush RheumNow
9 months 2 weeks ago
Finding the Right Combination Therapy in RA
Dr. Jonathan Kay interviews Dr. Ernest Choy about abstract 0521, Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in RA, presented at… https://t.co/yPmDIZ6aKI https://t.co/cairKrbDDu


Dr. John Cush RheumNow
9 months 2 weeks ago
RheumNow Day 4 Recap: ACR Convergence 2024 Highlights https://t.co/WvQB7y0bkm

Dr. John Cush RheumNow
9 months 2 weeks ago
Are we under-monitoring in scleroderma ILD?
Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of… https://t.co/1y1VXGvqjp https://t.co/4ofh45cYwq


Richard Conway RichardPAConway
9 months 2 weeks ago
Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB https://t.co/keXw5Qg2ld


Mrinalini Dey DrMiniDey
9 months 2 weeks ago
Does CVD mortality risk change after stopping GC in RA?
➡️28078 incident GC users
➡️Incr mortality risk from CVD &infections persists post-cessation
➡️Risk never returns to pre-GC level after prolonged use
⏩Use GC at lowest dose for shortest time possible
Ab2673 #ACR24 @Rheumnow https://t.co/dtLU8obLke


Mrinalini Dey DrMiniDey
9 months 2 weeks ago
Ab2674 #ACR24
➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12
➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M
@RheumNow https://t.co/pFOo86tJTx
